Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 259 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Severe Acute Respiratory Syndrome Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Psychological Well-being and Burnout in Healthcare Workers During the COVID-19 (Coronavirus Disease 2019) Pandemic

NCT05394051
View directory record Official record
Conditions
COVID-19, Burnout, Burnout, Professional, Work-related Illness, Work-Related Stress, SARS-CoV-2 Infection
Interventions
Positive Affect Regulation sKills (PARK)
Behavioral
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
555 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Oct 13, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional

Efficacy and Safety of Tozorakimab in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen

NCT05624450
View directory record Official record
Conditions
Viral Lung Infection and Acute Respiratory Failure
Interventions
Tozorakimab, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
3,527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
75
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 67 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 13, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional

Convalescent Plasma as a Possible Treatment for COVID-19

NCT04442191
View directory record Official record
Conditions
COVID-19
Interventions
Convalescent plasma, Placebo
Biological
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
40 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 13, 2026, 7:15 PM EDT
Terminated Phase 2 Interventional Results available

Study of Varespladib in Patients Hospitalized With Severe COVID-19

NCT04969991
View directory record Official record
Conditions
Coronavirus Disease 2019, Disease Caused by Severe Acute Respiratory Syndrome Coronavirus 2
Interventions
Varespladib, Placebo
Drug
Lead sponsor
Ophirex, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
7
States / cities
Ventura, California • Miami, Florida • Munster, Indiana + 3 more
Source: ClinicalTrials.gov public record
Updated May 15, 2025 · Synced Oct 13, 2026, 7:15 PM EDT
Suspended Phase 1 Interventional

Safety and Effectiveness of Placental Derived Exosomes and Umbilical Cord Mesenchymal Stem Cells in Moderate to Severe Acute Respiratory Distress Syndrome (ARDS) Associated With the Novel Corona Virus Infection (COVID-19)

NCT05387278
View directory record Official record
Conditions
COVID-19 Acute Respiratory Distress Syndrome, Respiratory Distress Syndrome
Interventions
EV-Pure™ and WJ-Pure™, Placebo
Drug
Lead sponsor
Vitti Labs, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Liberty, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 7:15 PM EDT
Terminated Phase 1Phase 2 Interventional

Radiation Eliminates Storming Cytokines and Unchecked Edema as a 1-Day Treatment for COVID-19

NCT04366791
View directory record Official record
Conditions
Pneumonia, Coronavirus Infection in 2019 (COVID-19), Severe Acute Respiratory Syndrome (SARS) Pneumonia
Interventions
Low Dose Radiation Therapy
Radiation
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 29, 2022 · Synced Oct 13, 2026, 7:15 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

Dociparstat for the Treatment of Severe COVID-19 in Adults at High Risk of Respiratory Failure

NCT04389840
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19), Acute Lung Injury, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Interventions
Dociparstat sodium, Placebo
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years to 85 Years
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
12
States / cities
Birmingham, Alabama • Loxahatchee Groves, Florida • Augusta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 13, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

NCT05438602
View directory record Official record
Conditions
COVID-19
Interventions
Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir, Placebo for ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
25
States / cities
San Francisco, California • Washington D.C., District of Columbia • Doral, Florida + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 13, 2026, 7:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigating Severe Acute Respiratory Syndrome (SARS)

NCT00066209
View directory record Official record
Conditions
SARS Virus
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
400 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 13, 2026, 7:15 PM EDT
Not listed Phase 3 Interventional

Phase 3 Study to Evaluate Efficacy and Safety of Lenzilumab in Patients With COVID-19

NCT04351152
View directory record Official record
Conditions
Coronavirus Disease 2019 (COVID-19) Pneumonia
Interventions
Lenzilumab, Standard of Care
Biological · Drug
Lead sponsor
Humanigen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
18
States / cities
Phoenix, Arizona • Irvine, California • Los Angeles, California + 13 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2021 · Synced Oct 13, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional

Extracellular Vesicle Treatment for Acute Respiratory Distress Syndrome (ARDS) (EXTINGUISH ARDS)

NCT05354141
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS
Interventions
ExoFlo, Intravenous normal saline
Biological · Other
Lead sponsor
Direct Biologics, LLC
Industry
Eligibility
18 Years to 75 Years
Enrollment
970 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Davis, California + 29 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 13, 2026, 7:15 PM EDT
Completed No phase listed Observational

Implementation of Lung Protective Ventilation in Patients With Acute Respiratory Failure

NCT03225807
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, ARDS, Respiratory Distress Syndrome, Acute, Respiratory Insufficiency, Respiratory Distress Syndrome, Shock Lung, Severe Acute Respiratory Syndrome
Interventions
Not listed
Lead sponsor
Intermountain Health Care, Inc.
Other
Eligibility
18 Years and older
Enrollment
8,692 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Murray, Utah
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Oct 13, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

NCT05735717
View directory record Official record
Conditions
Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
Interventions
Fludarabine, Busulfan, Melphalan, Rituximab, Levetiracetam, Alpha/Beta T Cell-Depleted Hematopoietic Stem Cells, Thymoglobulin, Cyclophosphamide
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 60 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2030
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 13, 2026, 7:15 PM EDT
Completed No phase listed Observational

Immunogenicity and Safety of Commercially Available Vaccines Against SARS-CoV-2 (COVID-19) in Patients With Hematologic Malignancies

NCT04748185
View directory record Official record
Conditions
Monoclonal B-Cell Lymphocytosis, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, B-cell Non Hodgkin Lymphoma, Hodgkin Lymphoma
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
358 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 10, 2023 · Synced Oct 13, 2026, 7:15 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 13, 2026, 7:15 PM EDT
Terminated Phase 2 Interventional Results available

A Study of LY3127804 in Participants With COVID-19

NCT04342897
View directory record Official record
Conditions
COVID-19, Pneumonia
Interventions
LY3127804, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
13
States / cities
Phoenix, Arizona • Tucson, Arizona • Denver, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Oct 13, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Self-Collected Saliva Samples Without Viral Transport Media for COVID-19 Testing Via RT-PCR

NCT04604145
View directory record Official record
Conditions
SARS-CoV Infection, Polymerase Chain Reaction, Laboratory Testing
Interventions
SARS-CoV-2 testing on the Eppendorf Thermal Cycler PCR system using self-collected saliva as the specimen
Diagnostic Test
Lead sponsor
David Grant U.S. Air Force Medical Center
Federal
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Travis Air Force Base, California
Source: ClinicalTrials.gov public record
Updated Aug 30, 2021 · Synced Oct 13, 2026, 7:15 PM EDT
Completed Not applicable Interventional Results available

CGM Use in COVID19 Patients (Infection With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2))

NCT04756141
View directory record Official record
Conditions
Diabetes Mellitus, Covid19
Interventions
Continuous Glucose Monitor (CGM)
Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 4, 2023 · Synced Oct 13, 2026, 7:15 PM EDT
Terminated Phase 1 Interventional Results available

A Study to Measure the Amount of Study Medicine in Blood in Adult Participants With COVID-19 and Severe Kidney Disease

NCT05487040
View directory record Official record
Conditions
COVID-19
Interventions
PF-07321332 (nirmatrelvir)/ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
52
States / cities
Huntsville, Alabama • Granada Hills, California • Inglewood, California + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Oct 13, 2026, 7:15 PM EDT
Terminated Phase 3 Interventional Results available

A Study to Assess Pulsed Inhaled Nitric Oxide vs Placebo in Subjects With Mild or Moderate COVID-19

NCT04421508
View directory record Official record
Conditions
COVID-19, Coronavirus, Coronavirus Infection
Interventions
INOpulse, Placebo
Combination Product
Lead sponsor
Bellerophon Pulse Technologies
Industry
Eligibility
18 Years and older
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • San Diego, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 21, 2023 · Synced Oct 13, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Mobile Health-based Motivational Interviewing to Promote COVID-19 Vaccination

NCT05977192
View directory record Official record
Conditions
Vaccination Hesitancy
Interventions
Standard MI, Intensive MI, MOTIVACC, Ecological momentary assessment (EMA) messages
Behavioral
Lead sponsor
Oklahoma State University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
2
States / cities
Oklahoma City, Oklahoma • Stillwater, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 13, 2026, 7:15 PM EDT
Completed Phase 1 Interventional

Study to Assess Adverse Events and How Intravenous (IV) ABBV-47D11 and IV ABBV-2B04 Given Alone and in Combination Moves Through the Body of Adult Participants With Coronavirus Disease 2019 (COVID-19)

NCT04644120
View directory record Official record
Conditions
CoronaVirus Disease-2019 (COVID-19)
Interventions
ABBV-47D11, Placebo for ABBV-47D11, ABBV-2B04, Placebo for ABBV-2B04
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
11
States / cities
Glendale, California • Cutler Bay, Florida • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2021 · Synced Oct 13, 2026, 7:15 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Antibody Detection of Vaccine-Induced Secretory Effects

NCT04895475
View directory record Official record
Conditions
Covid19, Humoral Acquired Immunodeficiency, Coronavirus, SARS-CoV Infection
Interventions
SARS-CoV-2 vaccine
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
18 Years and older · Female only
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 13, 2026, 7:15 PM EDT
Recruiting No phase listed Observational

Long-Term Study of COVID-19 Infection and Long COVID

NCT07781501
View directory record Official record
Conditions
SARS CoV-2 Post-Acute Sequelae
Interventions
This study is observational. Only patients who have previously tested positive for SARS-CoV-2 infection or are experiencing ongoing symptoms.
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 75 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 13, 2026, 7:15 PM EDT